GLP-1 Weight-Loss Drugs: Rare Harms, Real Tradeoffs

New reporting and medical evidence are sharpening the picture of GLP-1 drug safety: serious complications appear uncommon, but some risks are real and worth discussing before and during treatment.
Federal Funding Opens the Door to U.S. Ibogaine Trials

The federal government is moving to study ibogaine, a psychedelic with both anecdotal promise and documented cardiac risks, starting with safety-focused groundwork.
FDA Eases Path for Some Peptide Compounds Amid Safety Debate

The federal government has moved to make some compounded peptide products more available even as FDA staff have warned the evidence for safety and effectiveness is thin.
U.S. health officials move toward wider access to controversial peptide injections

The Trump administration is advancing a policy that could make certain unapproved peptide injections easier to compound, even as FDA materials continue to flag safety and quality concerns.
FDA Peptide Review Could Ease Access, but Safety Questions Remain

Federal advisers have opened the door to temporary access for several unapproved peptide products, even as FDA warnings continue to stress that compounded versions are not reviewed for safety, effectiveness or quality.
FDA mifepristone review stretches into 2027 as debate continues

The FDA says its ongoing safety review of mifepristone will continue into next year, keeping one of the nation’s most closely watched drug-policy fights in motion.